Federal drug price watchdog consulting public on proposed changes to its pricing guidelines

7 October 2022 - The PMPRB's guidelines explain how its staff monitor and review patented medicine prices to ensure they are ...

Read more →

Canadian drug prices: new regulations could save billions of dollars

15 June 2022 - New drug price regulations set to come into effect next month could lower spending on patented ...

Read more →

After a 5 year fight to lower drug prices, Ottawa's pledge quietly falls apart

12 May 2022 - What began with a promise to protect Canadians ended with a commitment to support pharmaceutical companies. ...

Read more →

Canada is settling for half measures on drug price regulations

22 April 2022 - After a two-year delay, new federal regulations for patented medicine prices will come into force this ...

Read more →

New PMPRB report shows significant consistency in public drug plan coverage across Canada for drugs subject to "Common Drug Review" process

22 February 2022 - The Patented Medicine Prices Review Board released today the third and final part in the Alignment ...

Read more →

Proposed PMPRB regulations requires focused dialogue with all players

16 February 2022 - Canada needs an approach that balances pricing considerations with the need to encourage investment, foster innovation, and ...

Read more →

Quebec to impose health tax on unvaccinated Canadians

12 January 2022 - The Canadian province of Quebec will charge a health tax to residents who are not vaccinated ...

Read more →

Canada should negotiate a fairer share of drug R&D costs

23 September 2021 - Instead of relying on price regulation, Canada should engage in negotiations about drug pricing. ...

Read more →

Canadian agency loses a battle in effort to force a drug maker to lower ‘excessive’ pricing

4 August 2021 - In a withering ruling, a Canadian appeals court overturned a controversial decision issued four years ago ...

Read more →

Court topples Canadian ruling that one of world's most expensive drugs is excessively priced

3 August 2021 - Soliris was originally approved to treat two blood disorders affecting about 180 Canadians, with the list price ...

Read more →

Canada again delays overhaul to patented medicine pricing system

29 June 2021 - Health Minister Patty Hajdu is delaying the first big overhaul of Canada’s patented medicines pricing system ...

Read more →

PMPRB risks harming the health of Canadians by reducing access to new medicines

23 June 2021 - On June 21, Innovative Medicines Canada submitted six recommendations to the federal government as part of the ...

Read more →

Put Canadians first by suspending the implementation of harmful drug pricing regulations

4 June 2021 - Innovative Medicines Canada calls on the federal government to suspend the implementation of the Patented Medicines ...

Read more →

Alberta, Canada, begins mandating switches from originator to biosimilar Humira

6 May 2021 - Alberta, Canada becomes the latest province to begin switching patients from originator adalimumab (Humira) to biosimilar ...

Read more →

Canada’s drug makers rattle their sabers over a government plan to control medicine spending

21 January 2021 - A majority of pharmaceutical executives in Canada say new regulations designed to cut prescription drug spending ...

Read more →